Case Report

Anesthesia Consideration in a Dog with Degenerative Valve Disease Undergoing Soft Tissue Surgery

Chattida Panprom1, Nakrob Pattanapon1, Wannisa Meepoo1, Soontaree Petchdee2*

1Kasetsart University Veterinary Teaching Hospital, Faculty of Veterinary Medicine, Kasetsart University, Kamphaeng Saen, Nakorn Pathom, Thailand; 2Department of Large Animal and Wildlife Clinical Science, Faculty of Veterinary Medicine, Kasetsart University, Kamphaeng Saen Nakorn Pathom, Thailand.

Received | August 22, 2022; Accepted | October 15, 2022; Published | November 01, 2022

*Correspondence | Soontaree Petchdee, Department of Large Animal and Wildlife Clinical Science, Faculty of Veterinary Medicine, Kasetsart University, Kamphaeng Saen Nakorn Pathom, Thailand; Email: [email protected]

Citation | Panprom C, Pattanapon N, Meepoo W, Petchdee S (2022). Anesthesia consideration in a dog with degenerative valve disease undergoing soft tissue surgery. Adv. Anim. Vet. Sci. 10(12): 2533-2537.

DOI | http://dx.doi.org/10.17582/journal.aavs/2022/10.12.2533.2537

ISSN (Online) | 2307-8316

Copyright: 2022 by the authors. Licensee ResearchersLinks Ltd, England, UK.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Introduction

Degenerative heart valve disease (DVD) is the most common heart disease in ageing small-breed dogs (Mattin et al., 2015). With the increasing number of dogs with DVD requiring surgical treatment, an appreciation of the impact of surgical and anesthetic treatments in the care of heart disease is essential. Previous studies have found that the risk of anesthetic death and the incidence of anesthetic complications in dogs increases with age (Matthews et al., 2017). Surgical treatment can induce cardiac dysfunction, and dogs with heart valve disease who are undergoing surgery are often considered to be at higher risk of mortality and morbidity. However, proper care planning and the management of anesthetic drugs may help reduce this risk. An important aspect of anesthesia in dogs with valvular heart disease is the choice of anesthesia drugs, which may affect cardiac function, as well as the rate of fluid delivery during anesthesia. Anesthetic drugs that are commonly used in veterinary medicine include xylazine, ketamine, and propofol (Carter et al., 2013). Previous studies have reported anesthesia-related morbidity and mortality with the use of xylazine and isoflurane (Dyson et al., 1998). Recent studies have shown toxic effects such as inducing cell injury and inflammation of the intravenous anesthetic propofol which is frequently used in dogs (Bosnjak et al., 2016). Alfaxalone is a neuroactive steroid drug that has been confirmed for the induction or maintenance of anesthesia in dogs and cats in several countries over the past few years. A previous study showed that alfaxalone preserves cardiovascular functions and is safe for surgical use in dogs (Chiu et al., 2016; Pattanapon et al., 2018). Therefore, this case report presents a specific anesthesia protocol using alfaxalone and provides guidelines including fluid management during general anesthesia for dogs with heart valve disease.

Case History

The present case report describes three surgical cases in dogs with moderate to severe valve regurgitation (Table 1). The mean age and weight were 16±0.6 years and 4.2±0.8 kilograms, respectively. All dogs were categorized according to the American Society of Anesthesiologists (ASA) physical status 3.

Table 1: The table contains the breed, gender, age, weight, and DVD stage of the dogs included in the study.

Dog owners were provided a consent form to approve the therapeutic procedure. A pre-anesthesia evaluation was performed, which comprised of routine history and physical examination, and laboratory parameters, including hematology, serum biochemistry, and electrolyte level analyses as shown in Table 2. A full cardiac examination was performed before and after the operation as shown in Tables 3 and 4.

Table 2: Blood profiles of three dogs.

Table 3: Echocardiography parameters of three dogs.

Table 4: The respiratory and cardiovascular parameters of three dogs.

Cardiomegaly was diagnosed on chest radiography in all three cases. A thoracic radiograph is shown in Figure 1.

Echocardiography and heart rate variability measurement

The severity of valve regurgitation was determined noninvasively via echocardiography (vivid s5, USA). Echocardiography was performed in parasternal long and short axis views and apical four-chamber views in the right and left parasternal positions with no sedation. Echocardiographic images were captured and stored for offline analysis. The left atrium dimension was measured by a standard left atrium to aorta ratio (LA/Ao). Left ventricular wall structure and function were calculated by measuring the images from two-dimensional and M-mode planes (Figure 2). Heart rate variability was measured by placing five electr--odes on the skin of the thorax to provide the ECG recordings (BTL Medical Technologies, Thailand).

Our study reported the techniques for anesthetic management in dogs with moderate to severe valvular degeneration during general anesthesia for soft tissue surgery. In all three cases included in this study, the advanced stages of degenerative valve disease and ventricular systolic, and diastolic dysfunction were presented and were typically masked by eccentric hypertrophy along with a markedly dilated left atrium. The left ventricle became less compliant, and the filling pressures increased. Measuring only the left ventricular functions, such as fractional shortening, may underestimate the severity of myocardial dysfunction. Dogs with chronic valve disease can experience pulmonary vascular changes, pulmonary hypertension, and right ventricular impairment. The tricuspid annular plane systolic excursion (TAPSE) is well correlated with the right heart function. A previous study reported that TAPSE <110 mm showed right ventricle dilation at the basal level and a worse degree of tricuspid regurgitation. In addition, isovolumic relaxation time (IVRT) and the E/A ratio are important echocardiography parameters for indicating an impairment of diastolic function (Petchdee et al., 2022). Not only the severity of valve regurgitation but also heart function, such as contraction and relaxation, must be considered. In addition, dogs with valvular heart disease with symptoms such as dyspnea, should undergo an anesthetic risk evaluation and consider a more detailed preoperative evaluation such as a chest X-ray and full scan echocardiography should be considered to reduce the potential risk of respiratory failure during general anesthesia.

Moreover, dogs should be treated with afterload reduction, diuretics, and inotropic support before surgery. Angiotensin-converting enzyme (ACE) inhibitors are frequently administered to dogs with chronic heart valve regurgitation. However, ACE inhibitors have been reported to be associated with perioperative hypotension. Thus, the ACE inhibitors should be withdrawn perioperatively, and continuous blood pressure monitoring should be considered for dogs with impaired myocardial function and presenting signs of congestive heart failure. Inotropic agents with β-1 agonistic effects, such as dobutamine or epinephrine should be prepared in cases of systemic hypotension.

The general anesthetic goals are to promote forward flow by maintaining a high heart rate and less afterload. The results of this study are similar to a previous report that the anesthetic protocol using diazepam and alfaxalone produced an increase in HR and influenced sympathetic activity (Pattanapon., 2018). These results suggested that diazepam and alfaxalone might preserve the cardiac autonomic activity balance. Using fluid maintenance during anesthesia can cause hypervolemia complications in patients with cardiovascular disease. An initial crystalloid fluid rate of 5 mL/kg/hr is recommended for healthy dogs undergoing anesthesia (Davis et al., 2013). In this study, we recommended providing a maintenance rate of 5 mL/kg/hr for dogs with heart valve disease and undergoing general anesthesia for soft tissue surgery. However, therapy must be individualized and adjusted to each dog.

Conclusions and recommendations

Previous studies have reported the risk of operative morbidity and mortality in patients with cardiovascular diseases. This report suggests that the anesthetic drug protocol of diazepam plus alfaxalone and a maintenance fluid rate of 5 mL/kg/hr for dogs with valve disease is safe and appropriate for preserving cardiovascular function.

Acknowledgments

The authors are grateful to the owner and Kasetsart Veterinary Teaching Hospital Kamphaeng Saen, Thailand for providing the necessary facilities.

Novelty statement

The novelty of this case report is the guidance protocol to assist veterinarians in selecting appropriate anesthetic drugs and managing dogs with heart disease.

Conflict of interest

The authors declare that there is no conflict of interest.

Author’s contribution

All the authors contributed to the manuscript. Chattida Panprom, Wannisa Meepoo, and Nakrob Pattanapon prepared and interpreted the results and Soontaree Petchdee drafted, critically revised, and approved a manuscript.

References

Beiseigel M., Simon B.T., Michalak C., Stickney M.J., Jeffery U. (2021). Effect of peri-operative crystalloid fluid rate on circulating hyaluronan in healthy dogs: A pilot study. Vet. J. 267: https://doi:10.1016/j.tvjl.2020.105578

Bosnjak Z.J., Logan S., Liu Y., Bai X. (2016). Recent Insights into Molecular Mechanisms of Propofol-Induced Developmental Neurotoxicity: Implications for the Protective Strategies. Anesthes. Analg. 123(5):1286-1296. https://doi.org/10.1213%2FANE.0000000000001544

Carter J., Story D.A. (2013). Veterinary and human anesthesia: an overview of some parallels and contrasts. Anesthes. Intens. Care. 41(6): 710-718. https://doi.org/10.1177/0310057x1304100605

Chiu K.W., Robson S., Devi J.L., Woodward A., Whittem T. (2016). The cardiopulmonary effects and quality of anesthesia after induction with alfaxalone in 2-hydroxypropyl-β-cyclodextrin in dogs and cats: a systematic review. J. Vet. Pharmacol. Therapeut. 39(6): 525-538. https://doi.org/10.1111/jvp.12312

Davis H., Jensen T., Johnson A., Knowles P., Meyer R., Rucinsky R., Shafford H. (2013). AAHA/AAFP Fluid therapy guidelines for dogs and cats. J. American Anim. Hosp. Assoc. 49:149-159. https://doi.org/10.5326/jaaha-ms-5868

Dyson D.H., Maxie M.G., Schnurr D. (1998). Morbidity and mortality associated with anesthetic management in small animal veterinary practice in Ontario. J. American Anim. Hosp. Assoc. 34(4): 325-335. https://doi.org/10.5326/15473317-34-4-325

Mattin M.J., Boswood A., Church D.B., López-Alvarez J., McGreevy P.D., O’Neill D.G., Thomson P.C., Brodbelt D.C. (2015). Prevalence of and risk factors for degenerative mitral valve disease in dogs attending primary-care veterinary practices in England. J. Vet. Inter. Med. 29(3): 847-854. https://doi.org/10.1111%2Fjvim.12591

Matthews N.S., Mohn T.J., Yang M., Spofford N., Marsh A., Faunt K., Lund E.M., Lefebvre S.L. (2017). Factors associated with anesthetic-related death in dogs and cats in primary care veterinary hospitals. J. American Vet. Med. Assoc. 250(6): 655-665. https://doi.org/10.2460/javma.250.6.655

Pattanapon N., Bootcha R., Petchdee S. (2018). The effects of anesthetic drug choice on heart rate variability in dogs. J. Adv. Vet. Anim. Res. 5(4): 485-489. https://doi.org/10.5455%2Fjavar.2018.e303

Petchdee S., Yalong M., Kaewnet M., Ithisariyanont B., Padawong T. (2022). Assessment of Right Ventricular Function, Blood Lactate Levels, and Serum Peptidomics Profiles Associated with Mitral Valve Disease in Dogs. Frontier Vet. Sci. 20: 8:789137. https://doi.org/10.3389/fvets.2021.789137